Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 23
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
TG Therapeutics Inc
TGTX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$53.16
-0.04
-0.08%
Ult. Agg.: Oct 22, 4:00 PM
$53.16
-0.04
-0.08%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
TG Therapeutics Financials
TG Therapeutics (TGTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
TG Therapeutics Raises FY2026 Sales Guidance from $925.000M to $950.000M vs $942.370M Est
TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $925.000 million to $950.000 million vs $942.370 million estimate.
Benzinga Newsdesk
PRO
TG Therapeutics Q2 EPS $0.05 Misses $0.33 Estimate, Sales $240.335M Beat $229.721M Estimate
TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.33 by 84.85 percent. This is a 70.59 percent decrease over earnings of $0.17 per share from
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
TG Therapeutics Q1 Adj. EPS $0.18 Misses $0.30 Estimate, Sales $204.918M Beat $196.814M Estimate
TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.30 by 40 percent. This is a 500 percent increase over earnings of $0.03 per share from the
Benzinga Newsdesk
PRO
TG Therapeutics Raises FY2026 Sales Guidance from $875.000M-$900.000M to $925.000M vs $906.021M Est
TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $875.000 million-$900.000 million to $925.000 million vs $906.021 million estimate.
Benzinga Newsdesk
TG Therapeutics Q4 Earnings Assessment
Benzinga Insights
